Výsledky vyhledávání - "Andrew John Thorpe"

Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Infection Rates from the Ulcerative Colitis Clinical Programme

Autor: Leonardo Salese, Rajiv Mundayat, Chinyu Su, Gary S. Friedman, Nervin Lawendy, Kevin L. Winthrop, Gary Chan, Walter Reinisch, Chudy I. Nduaka, Edward V. Loftus, Andrew John Thorpe, Daniel C. Baumgart

Publikováno v: Journal of Crohn's & Colitis

Background and Aims Tofacitinib is an oral, small molecule JAK inhibitor for the treatment of ulcerative colitis. We report integrated analyses of infections in the Phase [P]2 and P3 OCTAVE programmes. Methods Three cohorts were analysed: Induction [

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7744bb9ab6fd07bfa4bec39ecc7c0753
https://doi.org/10.1093/ecco-jcc/jjaa233

Zobrazit plný text záznamu

Tofacitinib in Patients with Ulcerative Colitis: Inflammatory Bowel Disease Questionnaire Items in Phase 3 Randomized Controlled Induction Studies

Autor: E Maller, Leonardo Salese, Marco DiBonaventura, Andrew G. Bushmakin, Haiyun Fan, Julián Panés, Marla Dubinsky, Joseph C. Cappelleri, Andrew John Thorpe

Publikováno v: Inflammatory Bowel Diseases

Background Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of ulcerative colitis (UC). We examined the effect of tofacitinib induction treatment on Inflammatory Bowel Disease Questionnaire (IBDQ) items in adults with m

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::739955a67ed2e300544fd2de66fa5814
https://doi.org/10.1093/ibd/izaa193

Zobrazit plný text záznamu

Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program

Autor: Kevin L. Winthrop, Eric L. Simpson, Emma Guttman-Yassky, Ricardo Rojo, Jonathan I. Silverberg, Andrew John Thorpe, Hernan Valdez, Susan Johnson, William Romero, Min Zhang, Alexander Egeberg, Audrey Nosbaum, Saleem A. Farooqui, Karin M. Hoffmeister

Publikováno v: Am J Clin Dermatol
American Journal of Clinical Dermatology

Background Pivotal phase III studies demonstrated that abrocitinib, an oral, once-daily, JAK1-selective inhibitor, is effective treatment for moderate-to-severe atopic dermatitis (AD) as monotherapy and in combination with topical therapy. Objective

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55d643cd18f33a6b23ad3861a191a92c
https://pubmed.ncbi.nlm.nih.gov/34642878

Zobrazit plný text záznamu

P598 Incidence of venous thromboembolic events in patients with ulcerative colitis treated with tofacitinib in the ulcerative colitis clinical development programme: An update as of May 2019

Autor: Walter Reinisch, Julià Panés, Silvio Danese, Bruce E. Sands, Chinyu Su, Nana Koram, Andrew John Thorpe, Daniel Quirk, Irene Modesto, Nervin Lawendy, Thomas V. Jones, W J Sandborn, Flavio Steinwurz, Kenneth Kwok

Publikováno v: Journal of Crohn's and Colitis. 14:S498-S500

Background Tofacitinib is an oral, small-molecule JAK inhibitor for the treatment of UC. In data analysed from a large, ongoing (data cut-off February 2019 [a]; database unlocked; data may be subject to change), post-authorisation safety study in pat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::966b7603fe30c7a581016c65c66de303
https://doi.org/10.1093/ecco-jcc/jjz203.726

Zobrazit plný text záznamu

Maintenance of Remission With Tofacitinib Therapy in Patients With Ulcerative Colitis

Autor: Leonardo Salese, Gary S. Friedman, Nervin Lawendy, Mark T. Osterman, Haiying Zhang, Chinyu Su, Andrew John Thorpe, Daniel Quirk, Chudy I. Nduaka, Walter Reinisch, Jean-Frederic Colombel

Publikováno v: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 20(1)

Background & Aims Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of ulcerative colitis (UC). The efficacy and safety of tofacitinib in patients with moderate to severe UC, up to 1 year, have been reported. We investig

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a39fee7c5f21f02beaf5575c15bdae8e
https://pubmed.ncbi.nlm.nih.gov/33039585

Zobrazit plný text záznamu

Tofacitinib, an Oral Janus Kinase Inhibitor: Analysis of Malignancy (Excluding Nonmelanoma Skin Cancer) Events Across the Ulcerative Colitis Clinical Program

Autor: Chudy I. Nduaka, Nervin Lawendy, Julián Panés, Ronald Pedersen, Chinyu Su, Gary R. Lichtenstein, Gerhard Rogler, Gary Chan, Andrew John Thorpe, Matthew A. Ciorba, Daniel Quirk

Publikováno v: Inflammatory Bowel Diseases

Background Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of ulcerative colitis (UC). Here, we performed an integrated analysis of malignancy events from the tofacitinib phase 3 UC clinical development program (exclud

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::88f86ba469e0f381cb0ab63815724a0b
https://pubmed.ncbi.nlm.nih.gov/32766762

Zobrazit plný text záznamu

Neuropathic pain: a narrative review of etiology, assessment, diagnosis, and treatment for primary care providers

Autor: Yvonne D'Arcy, Regina Behar, Bruce Parsons, Alesia Sadosky, Andrew John Thorpe, Bill H. McCarberg

Publikováno v: Current Medical Research and Opinion. 33:1361-1369

Background: Neuropathic pain (NeP) is a distinct type of chronic pain that is a direct result of damage to the nervous system itself. Studies have shown that training on the topic of chronic pain in medical schools is lacking and many practitioners a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d9423c14f0e263a7f1cc2daf741ca786
https://doi.org/10.1080/03007995.2017.1321532

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání